Demant revises expectations and resumes share buybacks
Q3 results beat expectations driven by Oticon Reveal. Organic growth is estimated at 7-8%, EBIT to DKK 4.7-5.0 bn, and a share buyback of at least DKK 3 bn is planned.
See the latest news and media coverage for Demant. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global hearing healthcare products and services group
demant.comLast updated
In short: Demant raised its 2026 outlook after strong Q3 results driven by the successful Oticon Reveal launch.
Q3 results beat expectations driven by Oticon Reveal. Organic growth is estimated at 7-8%, EBIT to DKK 4.7-5.0 bn, and a share buyback of at least DKK 3 bn is planned.
Organic growth of 7% exceeded expectations. The company expects organic growth of 6-7% and higher EBIT for the full year.
Driven by Oticon Zeal launch and KIND acquisition, the company maintains its financial outlook despite tariff impacts.
Chairman Niels B. Christiansen steps down after nearly two decades. Kristian Villumsen becomes the new chairman. The company achieved organic growth of 2% in 2025.
Investing.com -- Demant A/S (DEMANT.CO) shares rose about 3% following the company’s upgraded financial outlook for 2026 and announcement of resumed share buybacks.
Demant (DEMANT DC) lifts its FY26 organic growth guidance to between 7-8% (prev. guided 6-7%) and EBIT before special items between DKK 4.7-5bln (prev. guided...
The hearing aid group Demant is raising its forecasts for 2026. The company stated this in a corporate announcement. Demant now expects an operating result (EBIT) before special items between 4.7 and...
Demant A/S is the world's 2nd leading producer of audio products. Net sales break down by family of products as follows: - hearing care products...
Track Demant and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Demant and other trending companies.